Uncategorized
STAT+: Are analysts too quick to gloss over Lilly’s liver case?
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. I was having a fine day yesterday until my colleague shared this game that tests how good (or how bad in my case) your color perception is.
The need-to-know this morning
- Vertex Pharma reported first-quarter earnings that generally matched consensus, although the company said it was shelving an early stage, mRNA-based therapy for cystic fibrosis due to poor tolerability. The drug, called VX-522, was being developed as part of a collaboration with Moderna.
- Pfizer and Alkermes also reported earnings.
- Viridian Therapeutics announced positive top-line results from a Phase 3 study of its drug, called elegrobart, in patients with chronic thyroid eye disease.
Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease
Cytokinetics said its drug Myqorzo significantly improved heart failure symptoms and cardiovascular fitness in patients with non-obstructive hypertrophic cardiomyopathy, an inherited heart disorder.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. I was having a fine day yesterday until my colleague shared this game that tests how good (or how bad in my case) your color perception is.
The need-to-know this morning
- Vertex Pharma reported first-quarter earnings that generally matched consensus, although the company said it was shelving an early stage, mRNA-based therapy for cystic fibrosis due to poor tolerability. The drug, called VX-522, was being developed as part of a collaboration with Moderna.
- Pfizer and Alkermes also reported earnings.
- Viridian Therapeutics announced positive top-line results from a Phase 3 study of its drug, called elegrobart, in patients with chronic thyroid eye disease.
Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease
Cytokinetics said its drug Myqorzo significantly improved heart failure symptoms and cardiovascular fitness in patients with non-obstructive hypertrophic cardiomyopathy, an inherited heart disorder.